Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

Curanex (NASDAQ: CURX) is expanding its development pipeline to add cancer cachexia as a new core indication, citing a large unmet need and commercial opportunity.

Rhea-AI Summary

Curanex (NASDAQ: CURX) is expanding its development pipeline to add cancer cachexia as a new core indication, citing a large unmet need and commercial opportunity. The company notes the global market was about $2.54 billion in 2024, projected to $3.90 billion by 2033, and plans to evaluate development paths while advancing lead program Phyto-N.

Positive

• Global market estimated at $2.54B (2024), projected to $3.90B by 2033
• New core indication: cancer cachexia expands therapeutic focus and pipeline breadth
• Lead program Phyto-N advancing preclinical with planned IND submission

Negative

• No approved therapies for cancer cachexia in the United States
• Development-stage risk: Phyto-N is preclinical, subject to IND and clinical uncertainty

Argus Apr 2 session

-3.90% close to close Open Argus

Details

News Market Reaction – CURX

In the Apr 2 session, CURX declined 3.90%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands Curanex’s pipeline focus to cancer cachexia, a serious oncology complicati...

Analysis

This announcement expands Curanex’s pipeline focus to cancer cachexia, a serious oncology complication with no approved U.S. therapies and a global market estimated at $2.54 billion in 2024, rising to $3.90 billion by 2033. It complements ongoing work on Phyto-N and a planned IND for ulcerative colitis. Investors should track concrete development plans in cachexia, IND timing, cash resources from prior financings, and any future regulatory milestones.

Key Figures

Core indications pre-expansion: 6 indications Cancer cachexia prevalence: Up to 80% of advanced cancer patients Cancer cachexia market 2024: $2.54 billion +1 more

Core indications pre-expansion

6 indications

Ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout

Cancer cachexia prevalence

Up to 80% of advanced cancer patients

Estimated by National Cancer Institute

Cancer cachexia market 2024

$2.54 billion

Global market size in 2024 (Grand View Research)

Projected market 2033

$3.90 billion

Global cancer cachexia market projection for 2033

Historical Context

5 past events · Latest: Mar 30

5 events

1. Mar 30

   Business update

   24h Move

   +4.8%

   Business update on Phyto-N progress and funding alongside 2025 10-K.

2. Mar 18

   Preclinical results

   24h Move

   +10.4%

   Favorable maximum-dose toxicology data for Phyto-N supporting planned IND.

3. Mar 12

   Board expansion

   24h Move

   -11.6%

   Added immunology and infectious disease experts to Scientific Advisory Board.

4. Mar 11

   Board appointments

   24h Move

   +6.2%

   Appointed two veteran pharma leaders to guide strategy and portfolio.

5. Mar 05

   Board formation

   24h Move

   -5.0%

   Announced creation of five-member Scientific Advisory Board for R&D support.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cancer cachexia, ulcerative colitis, atopic dermatitis, nonalcoholic fatty liver disease, +2 more

6 terms

cancer cachexia medical

"by focusing on a new core indication: cancer cachexia, a serious cancer-associated"

A severe, involuntary wasting syndrome seen in some cancer patients that causes rapid loss of weight, muscle and strength despite normal or reduced food intake. It matters to investors because it worsens patient outcomes, complicates cancer treatment and creates demand for drugs, nutritional products and care services aimed at slowing or reversing the wasting; think of it as the body losing structural support even while medical care continues.

ulcerative colitis medical

"encompassed six core indications: ulcerative colitis, atopic dermatitis, COVID-19,"

A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

atopic dermatitis medical

"encompassed six core indications: ulcerative colitis, atopic dermatitis, COVID-19,"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

nonalcoholic fatty liver disease medical

"diabetes, nonalcoholic fatty liver disease (“NAFLD”), and gout, by focusing"

A condition where excess fat builds up in the liver in people who drink little or no alcohol, which can progress to inflammation, scarring and impaired liver function. Investors watch it because it represents a large and growing market for diagnostics, drugs and medical services, and its prevalence can affect healthcare costs, insurance payouts and workforce productivity—think of it as an expanding problem that creates both treatment demand and regulatory/clinical trial risk for companies.

NAFLD medical

"diabetes, nonalcoholic fatty liver disease (“NAFLD”), and gout, by focusing"

Non-alcoholic fatty liver disease (NAFLD) is a condition where the liver accumulates excess fat not caused by heavy alcohol use, ranging from harmless fat buildup to inflammation and scarring. Think of the liver as a household filter that gets clogged with grease: mild clogging may be reversible, but long-term damage can lead to costly medical care and reduced productivity. For investors, NAFLD matters because it drives demand for diagnostics, treatments and related healthcare services, creating opportunities and risks across pharmaceuticals, medical devices and healthcare providers.

investigational new drug (IND) regulatory

"preclinical studies in preparation for a planned Investigational New Drug (IND) submission"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company expands strategic focus into one of oncology’s 
most urgent supportive-care challenges

Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage therapeutics company, today announced that it is expanding its drug development pipeline that encompassed six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (“NAFLD”), and gout, by focusing on a new core indication: cancer cachexia, a serious cancer-associated wasting syndrome marked by progressive weight loss, muscle depletion, weakness and declining physical function.

Cancer cachexia is widely recognized as one of the most serious complications in oncology and is estimated by the National Cancer Institute to occur in up to 80% of patients with advanced cancer, depending on cancer type and response to treatment. The syndrome can severely reduce strength, impair quality of life and limit a patient’s ability to tolerate therapy. Despite its significant clinical burden, there are currently no approved therapies for cancer cachexia in the United States.

Curanex believes the combination of major unmet need, limited treatment options and growing clinical recognition supports a significant long-term commercial opportunity in cancer cachexia. According to Grand View Research, the global cancer cachexia market was approximately $2.54 billion in 2024 and is projected to grow to $3.90 billion by 2033.

Curanex’s lead program, Phyto-N, is currently advancing through preclinical studies in preparation for a planned Investigational New Drug (IND) submission for ulcerative colitis. As it advances that program, the Company is also evaluating additional development opportunities in serious diseases involving inflammation, metabolic dysfunction and physical decline.

Curanex Chief Executive Officer, Jun Liu, said “Cancer cachexia remains one of the largest unmet needs in supportive oncology, with serious consequences for patients and very limited treatment options. We believe this area represents a meaningful opportunity for focused drug development and an important step in the evolution of Curanex into a broader therapeutics development company.”

Curanex management believes that the focus on treatment of cancer cachexia aligns with the Company’s broader focus on treatment of serious diseases involving inflammation, metabolic disruption and physical decline. While Curanex remains committed to advancing its lead ulcerative colitis program, the Company believes that by expanding its long-term pipeline potential by also focusing on cancer cachexia treatment, the Company will strengthen its positioning as an emerging therapeutics company.

About Curanex Pharmaceuticals Inc.

Curanex Pharmaceuticals Inc. is a development-stage therapeutics company headquartered in Jericho, New York. The Company is advancing drug development programs for serious diseases with significant unmet medical need. Its lead candidate, Phyto-N, is currently being advanced through FDA-required preclinical studies in preparation for a planned IND submission for ulcerative colitis. Curanex is also evaluating broader development opportunities intended to expand its long-term therapeutic pipeline.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements are made as of the date hereof and involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions.

The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors to read “Risk Factors” section of the Company’s Annual Report on Form 10-K dated March 30, 2026 (Inline Viewer: CURANEX PHARMACEUTICALS INC 10-K 2025-12-31) and risk factors contained in other filings with the Securities and Exchange Commission (the “SEC”) to gain understanding of the important factors that could cause actual results to differ materially from the anticipated results and projections about future events contained in this press release.

Contact:

Curanex Pharmaceuticals Inc
Tel: (212) 671-1020 / (718) 673-6078
Email: ir@curanexpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Curanex (CURX) announce on April 2, 2026 about its pipeline?

Curanex announced adding cancer cachexia as a new core indication to its pipeline. According to the company, this expands beyond six prior indications and aligns with its focus on inflammation, metabolic dysfunction and physical decline.

How large is the cancer cachexia market Curanex cited for CURX investors?

The market was cited at $2.54 billion in 2024, growing to $3.90 billion by 2033. According to the company, the figures come from Grand View Research and illustrate the commercial opportunity the company is targeting.

What development stage is Curanex's lead program Phyto-N (CURX) in as of April 2026?

Phyto-N is advancing through preclinical studies with a planned IND submission. According to the company, Phyto-N remains focused on ulcerative colitis while company explores cachexia development opportunities.

Why is cancer cachexia a strategic focus for Curanex (CURX)?

Cancer cachexia has high unmet need and limited treatment options, the company said, potentially improving supportive oncology care. According to the company, prevalence and clinical burden support a meaningful long-term commercial opportunity.

Does Curanex (CURX) claim existing approved treatments for cancer cachexia?

No, Curanex notes there are currently no approved therapies for cancer cachexia in the United States. According to the company, that regulatory gap contributes to the unmet medical need they aim to address.

How will adding cancer cachexia affect Curanex's long-term strategy for CURX?

The company says adding cachexia strengthens its evolution into a broader therapeutics developer. According to the company, the move complements its focus on inflammation, metabolic disruption and physical decline while advancing Phyto-N.